…Same drug, two European institutions, opposite verdicts — and twenty-seven pricing decisions still to come.
A few weeks ago, we argued that approval, access and adoption are three different events, and that the pharmaceutical industry is built to win the first while assuming the other two. The argument was structural. It now has an exhibit.
On 9 June 2026, the European Commission published the first Joint Clinical Assessment under the EU HTA Regulation, on Ipsen’s orphan cancer medicine tovorafenib. The European Medicines Agency had already approved the drug; that question was settled. The JCA asked the next one — not “is it safe and effective enough to sell,” but “is it better than what European systems already use.” After a twenty-page assessment, the answer it could give was: we cannot tell.
The EMA said yes. The JCA said it could not tell.
Two European institutions looked at the same medicine and reached opposite verdicts. That is not a contradiction to be explained away. It is the reason this publication exists.
The same drug, two answers
The answers diverge because the questions do. As we have covered, regulators ask whether a product works; payers ask whether it works better than the comparator they already fund, in the population they actually treat. Approval clears the first bar. It says nothing about the second.
The JCA is that second question, formalised at European level — and the evidence to answer it, for this drug, largely does not exist. The pivotal trial was single-arm and non-randomised, so there was no head-to-head comparison to assess. For seven of the eight population-and-comparator scenarios the assessment defined, no usable comparative data were available at all. For the one scenario where a comparison could be attempted, it rested on a statistically reweighted handful of patients, and even there the results refused to settle: at face value the existing combination showed a longer median time without progression and markedly fewer severe side effects, while the response data pointed in opposite directions depending on who read the scans. The assessors’ own conclusion was that the estimates should not be read as showing a real treatment effect in either direction.
So the EMA’s approval and the JCA’s assessment are not in conflict. They are answers to different questions — and the space between them is precisely the space between being allowed onto the market and being worth paying for.
This is not a flaw in the drug. It is the distance between two questions, made visible.
It bears saying plainly, because the easy reading is a cheap one. None of this means tovorafenib fails its patients. It treats children with a rare brain tumour, where randomised evidence is hard to generate and accelerated approval on single-arm data is a legitimate path. The drug may help. The point is not that it is bad. The point is that “the regulator approved it” and “the evidence shows it is worth more than the alternative” are different statements — and Europe has now produced an official document showing, in one case, exactly how far apart they can sit.
Harmonisation of the question, not the answer
Here is where the milestone framing quietly misleads. The JCA was sold, again, as the cure for European fragmentation: one assessment instead of twenty-seven, less duplication, faster and more equal access. At the level of the clinical dossier, that is real. The science was done once, jointly, and endorsed by every member state.
But the JCA assesses relative clinical effectiveness and safety, and nothing else. It contains no economic evaluation. It reaches no value judgement. It assigns no score, no rating, no recommendation. It does not decide reimbursement in a single country. What it produces is a shared, uncertainty-laden evidence base — which is then handed to twenty-seven national systems, each of which will now price, negotiate, and decide access through its own framework, its own threshold, and its own willingness to pay.
The next steps make this concrete. In Ireland, the company will now file for reimbursement, and the NCPE will weigh it nationally. In Germany, the same report feeds the AMNOG process and the G-BA’s benefit appraisal. Same European evidence, twenty-seven national verdicts — and the report cannot, by design, make any of them.
This is not harmonisation of the answer. It is harmonisation of the question.
Which means the thing everyone actually cares about — whether a Portuguese child reaches this drug as quickly as a German one — is left exactly where it was. We have written before about the European access gap: an average of 578 days from approval to availability, ranging from 128 in Germany to 840 in Portugal, with fewer than half of approved medicines available across the bloc on average. The JCA was never built to close that gap. It standardises the clinical evidence that goes into twenty-seven decisions; it does not standardise the decisions. A harmonised evidence base no more produces harmonised access than a shared weather forecast produces a shared destination.
Harmonised uncertainty is still uncertainty. It just has twenty-seven readers now.
What this means
The first JCA does not change the structure of European market access. It illuminates it. Three things follow.
First, do not mistake the JCA for the finish line. A clean joint assessment is the opening of twenty-seven national conversations, not a substitute for them. The clinical question is now answered once; the access question is answered as many times as there are member states, and on terms the JCA does not touch.
Second, the access gap will not close because the evidence was harmonised. The 578 days were never primarily a clinical-assessment problem. They are a pricing, budget, and political problem — and those decisions still happen country by country, after the JCA, in the language of affordability rather than evidence.
Third, the approval-to-access distance is now, for the first time, an official European artefact. When the EMA approves a medicine and the EU’s own HTA system publishes a report saying the comparative case is unproven, the gap between marketing authorisation and reimbursement stops being an abstraction that market access professionals explain in meetings. It becomes a document, with a publication date, that anyone can read.
We said it a few weeks ago: a medicine can be approved, reimbursed, listed, and still never reach the patient it was built for. Europe has now published the first chapter — the part where approval and access, asked to agree, openly did not.
The EMA decides whether a drug may be sold. The JCA describes how much we really know about whether it should be. And twenty-seven governments still decide, one at a time, whether anyone will pay.
Report: https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf
Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.